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Background: Invasive pulmonary aspergillosis (IPA) is an infection often occurring in neutropenic patients and has
high mortality rates. In recent years, it has been reported that the incidence of IPA has also increased in patients
with chronic obstructive pulmonary disease (COPD). The purpose of this study is to investigate the clinical and
demographic characteristics and treatment responses of IPA in patients with COPD.
Methods: Seventy-one patients with a positive culture of Aspergillus from lower respiratory tract samples were
examined retrospectively. Eleven (15.4%) of these patients, affected with grade 3 or 4 COPD, had IPA.
Results: Aspergillus hyphae were detected in lung biopsy in three (27.3%) out of 11 patients and defined as proven
IPA; a pathological sample was not taken in the other eight (72.7%) patients, and these were defined as probable
IPA. Aspergillus isolates were identified as six cases of Aspergillusfumigatus and three of Aspergillusniger in nine
patients, while two isolates were not identified at species level. While five patients required intensive care unit
admission, four of them received mechanical ventilation. The most common finding on chest X-ray and computed
tomography (CT) (respectively 63.6%, 72.7%) was infiltration. Amphotericin B was the initial drug of choice in all
patients and five patients were discharged with oral voriconazole after amphotericin B therapy. Six patients (54.5%)
died before treatment was completed.
Conclusions: IPA should be taken into account in the differential diagnosis particularly in patients with severe and
very severe COPD presenting with dyspnea exacerbation, poor clinical status, and a new pulmonary infiltrate under
treatment with broad-spectrum antibiotics and steroids.
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Invasive Pulmonary Aspergillosis (IPA) is frequently
seen in patients with hematologic malignancy, allogenic
bone marrow transplantation, the late stage of HIV
infection, solid organ transplantation, and chronic gra-
nulomatosis [1-3]. In addition, the number of studies
stating that IPA is increasing in cases with chronic
obstructive pulmonary disease (COPD) has gradually
risen in recent years [3-7].
In COPD patients ciliary activity impairment, im-
munosuppression due to alveolar macrophage and neu-
trophil inhibition in those treated with steroids and* Correspondence: drnuritutar@gmail.com
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reproduction in any medium, provided the oralso receiving broad-spectrum antibiotics, play a role in
the development of IPA [8,9]. In a review, in which
1,941 patients followed up with the diagnosis of IPA
were examined, COPD was detected in 1.3% of all cases
[10]. In a study carried out in the years following this
review, it was found that the frequency of IPA in COPD
cases in 2007 had increased approximately more than
twice with respect to the year 2000 in the same hospital
[6]. This finding shows that the rate of IPA incidence in
COPD patients is ever increasing. Based on this study
carried out in Spain we planned to report our IPA cases
with COPD. Hence, in the present study we aimed to
investigate the clinical and demographic features of
IPA in patients with COPD and also to examine the
treatment outcomes and mortality rates.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Study population and case descriptions
This retrospective study was carried out on patients who
applied to Erciyes University Hospital, which has 1,300
in-patient bed availability. It was approved by the Ethics
Review Board of Erciyes University (2013/269).
COPD diagnosis was established according to the Glo-
bal Initiative for Chronic Obstructive Lung Disease
(GOLD) criteria [11]. In patients with COPD, Bulpa cri-
teria were used for IPA diagnosis [5]. Accordingly, the
diagnosis of “proven IPA” was established by means of
the presence of hyphae compatible with Aspergillus in
the examination of specimens taken from a pulmonary
lesion through pulmonary biopsy or needle aspiration,
and by the isolation of Aspergillus species in culture
from any upper respiratory tract (URT) sample together
with evidence of associated tissue damage. The diagnosis
of “probable IPA”, it was established by the coexistence
of host factors [patient with severe COPD according to
GOLD (stage III or IV), usually treated with steroids,
with recent exacerbation of dyspnoea, and suggestive
chest imaging] and microbiological factors [Aspergillus
isolation in LRT sample or two sequential positive serum
galactomannan (GM) tests]. The diagnosis of “possible
IPA” required host factors, but without microbiological
proof, while “colonization” meant the patient was asymp-
tomatic in spite of the isolation of Aspergillus in the lower
respiratory tract samples.
In our study, the response to antifungal treatment
was evaluated based upon the criteria determined by the
European Organization for the Research and Treatment of
Cancer (EORTC) and the Mycoses Study Group (MSG)
[12]. Accordingly, a reduction of at least 25% in the diam-
eter of radiological lesions, together with recovery in the
findings of disease and disease-specific symptoms and the
patient’s being alive at the end of treatment were defined
as treatment success. As for treatment failure, it was de-
fined as follows: radiological stabilization (the 0-25% reso-
lution of lesion diameter) together with a slight or no
recovery in the findings of disease and coexistent symp-
toms despite the fact that the patient survived; the occur-
rence of disease in new areas together with the worsening
of findings and symptoms of disease clinically; radiological
deterioration of pre-existing lesion; continuous isolation of
fungus species from the infected area; the patient’s death
within the 12 week-follow up period for whatever reason.
Patient inclusion criteria and data collection
In the present study we examined the data on the isolation
of Aspergillus from LRT samples in our microbiology la-
boratory which were sent from the chest disease or infec-
tious disease clinics between January 2006 and December
2011. The inclusion criteria were as follows: 1- the isola-
tion of Aspergillus from LRT culture; 2- patients hadCOPD in GOLD stage 3 (severe) or 4 (very severe); 3- pa-
tients had a history of steroid use (systemic or inhaled) in
the last 3 weeks before admission or had a history of anti-
biotic use in the last 3 months before admission; 4- the
isolation was not considered as colonization. The patients
were diagnosed as “proven IPA” and “probable IPA”.
There was no case of “possible IPA” since only patients
with a positive culture for Aspergillus were included in
the study. The files, discharge reports and x-rays of all
patients, which were registered in the hospital data pro-
cessing system, were checked. Accordingly, we registered:
demographic features, history of smoking, presence of
other coexisting diseases, pulmonary function test re-
sults, history of drug use, clinical symptoms, results of
laboratory tests, imaging findings, hospitalization periods,
intensive care unit (ICU) admission, invasive mechanical
ventilation support , and response to treatment.
Microbiological procedures
In the course of the study period, following the direct
microscopic examination, all LRT specimens were cul-
tured on Sabouraud dextrose agar (SDA) media with and
without antibiotics. One of these was incubated at 37°C
and the others in incubators at 25°C for 3 weeks and were
evaluated as to whether isolation occurs 3 times in a week,
or not. The identification of a colony presenting mould
growth was carried out at species level according to
macroscopic and microscopic morphology [13].
The galactomannan (GM) antigen level in serum was
detected in all patients by Platelia Aspergillus Galac-
tomannan EIA kits (Bio-Rad, Marnes-La-Coquette,
France). The ratio of ≥ 0.5 ng/mL for GM was con-
sidered positive. A 1,3-beta D-Glucan level was detected
by Fungitell kits (Associates of Cape Cod, East Falmouth,
MA, USA) and a ratio of > 80 pg/mL was considered
positive [2].
Statistical method
The frequency, percentage, mean, standard deviation,
median and interquartile range values from descriptive
statistics are presented. The SPSS 15.0 packaged soft-
ware was used for the analysis of data.
Results
Diagnostic and demographic characteristics of patients
In 71 patients Aspergillus had been isolatedin LRT sam-
ples. Eleven out of them (15.4%) had stage 3 or 4 COPD
and these were the cases that applied to our hospital
with complaints of dyspnea. As a result of lung biopsy in
three cases (27.3%) out of these 11 patients, hyphae
compatible with Aspergillus were seen and identified as
proven IPA; in the other eight cases (72.7%), pathological
specimens were not taken and these were identified as
probable IPA.
Table 2 Symptoms, laboratory and radiological findings







Laboratory, average ± SD or median (IQR)
White blood cell, 103/mL 13.5 ± 5.2
Hemoglobin, g/dL 12.0 ± 2.8
Thrombocyte, 103/mL 352.1 ± 175.1
Sedimentation, mm/hour 88 ± 25
CRP, mg/L 117 ± 50
Galactomannan, ng/mL 0.54 (0.17-9.16)





Pleural fluid 2 (18.1)
Consolidation 2 (18.1)
Worsening radiological findingsa 7 (63.6)
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fumigatus and three as Aspergillus niger, while identifica-
tion at species level in the other two strains was not made.
The mean age was 65.1 ± 9.7 years and 9 patients
(81.8%) were male. History of smoking was present in 8
cases (72.7%). Ten patients (90.9%) had been using a sys-
temic steroid and 8 (72.7%) an inhaler steroid over the
last 3 weeks. History of antibiotic use was present in
four patients over the last 3 months. The average diag-
nosis time was 13.8 ± 3.8 days after admission and the
average hospitalization period was 24.7 ± 13.9 days. Five
cases had ICU admission and four of them received in-
vasive mechanical ventilation (Table 1).
Symptoms, laboratory results and radiological findings
The most frequent symptoms were dyspnea (n = 11,
100%) and cough (n = 10, 90.9%). Sputum, fever and
hemoptysis were other recorded symptoms (Table 2).
Moreover, GM was positive in nine patients (81.8%).
The median value for GM was 0.54 ng/mL. Beta D-
Glucan was examined in five patients and was positive
in three (60%) of them.
The most frequent abnormal finding seen in chest x-
ray was infiltration (n = 7, 63.6%). Cavitation, nodule,
consolidation and pleural fluid came next in order of
frequency. As for the thorax computed tomographyTable 1 Clinical and demographic characteristics of 11




Mean age, years 65.1 ± 9.7
Smoking history
Yes 8 (72.7)
>40, pack years 4 (36.3)
Underlying disease
Diabetes mellitus 1 (9.0)
Cardiovascular disease 3 (27.2)
Steroid treatmentb
Inhaled 8 (72.7)
Systemic use 10 (90.9)
Recent use of antibioticsc 4 (36.3)
Time to diagnosis, days 13.8 ± 3.8
Hospitalization period, days 24.7 ± 13.9
ICU admission 5 (45.4)
Mechanical ventilation 4 (36.3)
Death 6 (54.5)
aData are presented as number (%) or average ± standard deviation.






Pleural fluid 2 (18.1)
IQR, Interquartile range.
aNew images of infection appeared or old lesions worsened compared to
previous chest radiographs.(CT) findings, again infiltration was frequently en-
countered (n = 8, 72.7%). Nodule, consolidation, cavity
and pleural fluid was next in order of frequency
(Table 2). Progress in radiological findings for infec-
tion before antifungal treatment was detected in seven
cases (63.6%).
Antifungal treatment and results
Diagnostic procedures, treatment and results for all pa-
tients are shown in Table 3. In terms of treatment, all
cases received amphotericin B [7 (63.6%) amphotericin
B deoxycholate, 4 (36.4%) liposomal amphotericin B]
for initial treatment and 5 (45.4%) patients were
discharged with oral voriconazole. Six (54.5%) patients
died before the completion of treatment and were con-
sidered as “treatment failure”. In 5 patients (45.4%),
Table 3 Diagnosis, antifungal therapy, and outcomes in 11 COPD patients with IPA





1 Probable Steroid Infiltration,
cavitation
Infiltration, cavity Sputum, pleural fluid A. niger LAMB 3.79→ 0.24 none Yes
2 Probable Steroid Infiltration Infiltration Bronchial lavage A. fumigatus LAMB 0.53→ none none Yes
3 Probable Steroid Cavitation Cavity Sputum Aspergillus
species
AMB 3.79→ 2.33 none Yes








AMB 9.16→ none none Yes
5 Probable Steroid Consolidation Consolidation Bronchial lavage A. niger AMB 5.48→ 4.38 none Yes
6 Probable Steroid Cavitation, nodule Infiltration, cavity,
nodule
Sputum A. fumigatus AMB 0.22→ none > 523 Yes




Consolidation, nodule Sputum A. fumigatus AMB, then
voriconazole
0.54→ 0.33 59 No
8 Provenb Antibiotic Infiltration Infiltration, nodule Bronchial lavage A. fumigatus AMB, then
voriconazole
0.60→ 0.30 none No
9 Probable Steroid Infiltration Infiltration Bronchial lavage A. fumigatus AMB, then
voriconazole
0.50→ 0.16 51 No
10 Probable Steroid Infiltration, nodule Infiltration, nodule Sputum A. niger LAMB, then
voriconazole
0.17→ none 90 No
11 Provenb Steroid and
antibiotic
Infiltration Infiltration Transbronchial biopsy A. fumigatus LAMB, then
voriconazole
0.39→ none > 523 No
aThe term Steroid includes only systemic corticosteroid treatment.
bHyphae were seen in the pathological examination of biopsy material.
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treatment was followed up and these cases were ac-
knowledged as “treatment success”. In those patients in
whom treatment success was observed, the average
duration of treatment was 137.2 days; instead it was
15.8 days in the patients who died.
Discussion
In the present study, the diagnosis and treatment fea-
tures of 11 COPD cases, who had IPA but no other
immunosupressive diseases, were analyzed. In recent
years, it has been shown that corticosteroid use plays a
significant role in terms of increasing the rate of IPA in-
cidence in COPD cases [5,6]. In one retrospective study,
it was shown that steroid use of over 700 mg in total
within the last three months in COPD patients increased
the risk of IPA [6]. Also, it has been stated by some au-
thors that inhaled steroids are a risk factor for IPA [14].
While 72.7% of cases in this study had used an inhaled
steroid, 10 cases (90.9%) had used a systemic steroid
within the last 3 weeks.
Another risk factor charged with the development of
IPA in COPD patients is broad-spectrum antibiotic
treatment. In one study, it was pointed out that treat-
ment with a wide range of broad-spectrum antibiotics
used before hospitalization in COPD cases was associ-
ated with the development of IPA and another study
showed that using three or more antibiotics for 10
days was a risk factor for IPA development in patients
with COPD [15,16]. In the present study, similar to
other reports, four cases had used antibiotics in the
last 3 months and a history of antibiotic use was the
only risk factor in one case that did not receive sys-
temic steroid treatment.
Since underlying disease may mask the findings of
Aspergillus lung invasion, clinical symptoms and radio-
logical findings are nonspecific in cases with COPD
[6]. In COPD patients where IPA had developed, dys-
pnea was reported as the most frequent symptom and
cough, wheezing, increase in sputum amount and fever
may also be seen [16]. The most frequent radiologic
finding was infiltration [6,7] that is non specific and
may correspond to a COPD exacerbation caused by
bacterial pulmonary infection, frequently encountered
especially in chest disease clinics. For this reason, pa-
tients are frequently diagnosed as affected with IPA
following their hospitalization. In our study, we were
able to diagnose IPA in an average of 13.8 days after
hospitalization. This also shows that an early screening
test for IPA should be performed. In addition, the
isolation of Aspergillus strains in culture and no re-
gression in radiological and clinical findings with ap-
propriate antibiotic treatment are the most important
findings which suggest IPA. In this study, similar toother reports, the dyspnea was reported in all cases
and the chest x-rays of seven cases at follow up showed
a progression of findings compared to the chest x-ray
on hospital admission.
In studies carried out on patients with hematologic
malignancy from our country, GM antigen test sensitiv-
ity was found as 56-61% and its specificity as 21-84%
[17,18]. However, in studies carried out on COPD cases
in different centers, GM antigen test sensitivity in the
diagnosis of IPA was stated as 46.2-80% and specificity
as 83.3-94.1% [16,19,20]. In addition, it has been indi-
cated that GM positivity in COPD patients with IPA
development in intensive care and the isolation of Asper-
gillus species in respiratory samples may be significant
in terms of mortality [3]. As for our study, the GM value
was found to be positive in 9 (81.8%) cases, and 5 of
them (55.5%) died. This gives further support to the be-
lief that GM positivity in COPD cases with the develop-
ment of IPA is a significant parameter to be considered
in terms of mortality. Moreover, it is conceivable that a
GM value positive in the diagnostic period will become
negative in cases responding to treatment [21]. In 2 of
our 7 cases where the GM test was repeated after they
received antifungal treatment for at least one week, it
was found that GM value was still positive, in fact treat-
ment failed in both patients and they died (Table 3).
While 1,3-beta-D-glucan was found to be negative in
two cases for whom the GM value was positive, it was
found positive in three IPA cases with negative GM test.
In a study carried out recently, the sensitivity of the 1,3-
beta-D-glucan test in the diagnosis of IPA was reported
as 66% and its specificity as 75.6% [22]. Especially in pa-
tients from whom a bronchoscopic sample was not
taken, applying both serologic methods may increase
diagnostic sensitivity, although prospective systematic
studies analyzing this application in patients with COPD
are needed.
Even though amphotericin B has been used as the
first-line antifungal agent in the treatment of IPA for
many years, in a comparative study carried out in 2002
voriconazole was more successful than amphotericin B
as the primary mode of invasive aspergillosis treatment
[23]. Saito et al. also observed a good response as high
as 60.6% with voriconazole in patients with chronic
pulmonary aspergillosis [24]. In a recent study, Chu
et al. reported 108 invasive fungal infections treated
with voriconazole in whom 83 patients (76.8%) were
IPA [25]. Although the authors, in patients with
proven and probable invasive fungal disease, did not
find a significant relationship between therapeutic
voriconazole levels and achievement of complete or
partial response at 12 weeks, radiologic response was
noted in 55.2% of patients with invasive pulmonary as-
pergillosis. In addition, they found complete or partial
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levels in seven patients all affected with invasive pul-
monary aspergillosis. In the present study partial re-
sponse was achieved in 45.4% of patients and all
received voriconazole after initial amphotericin B ther-
apy. This was due to the fact that treatment in living cases
was continued with the use of voriconazole by virtue of its
oral form being available.
In the studies of different centers, the mortality rate
of IPA in COPD cases was reported to be between 43.3%
and 95% [5-7,16,26]. In our study, the mortality rate was
54.5%, however, to define the excess cause of mortality is
difficult in this patient group since they had a very lim-
ited lung function based on the stage of COPD.
Conclusions
In conclusion, we believe that “proven” or “probable”
IPA should be taken into account in differential diagno-
sis, particularly in patients with severe and very severe
COPD presenting with dyspnea exacerbation, poor clin-
ical status, and a new pulmonary infiltrate on chest
radiograph under treatment with broad-spectrum antibi-
otics and steroids. The presents study shows that the
LRT culture for Aspergillus, serum GM test and chest
imaging (x-ray and CT) can be useful for the early dif-
ferential diagnosis of IPA, and voriconazole should be
given for the treatment of such patients.
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